|
| 항정신병약물의 현재와 미래 |
|
Joo-Cheol Shim, MD, PhD1, Bo-Geum Kong, MD, PhD1, Do-Un Jung, MD2 and Sung-Soo Jung, MD3 |
|
|
|
|
| Abstract |
|
Although there are a number of theories regarding the mechanism of action of antipsychotic drug, the precise mechanism remains
incompletely understood. Currently approved antipsychotic drugs have at least affinity on dopamine receptors. Serotonin-dopamine
receptor antagonism has been considered as the primary mechanism of action of atypical antipsychotics, though “atypicality”
of those drugs is not clearly understood yet. There has been an increased interest in developing novel strategies for treating
the cognitive deficits in schizophrenia, because those are much better predictors of functional outcome than any other symptom
domains. The primary molecular targets for potential drug development for treating cognitive deficit include dopamine receptors
in prefrontal cortex, nicotinic and muscarinic acetylcholine receptors, the glutamatergic excitatory synapse, and others. In this
article we review the molecular target of currently approved and developing antipsychotic drugs, including drugs for improving
cognitive deficit in schizophrenia. (Korean J Schizophr Res 2008;11:11-19) |
| Key Words:
Schizophrenia,Antipsychotic drug,Mechanism of action. |
|
PDF Links
Full text via DOI
Download Citation
